ATC Group: J04AB02 Rifampicin

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J04AB02 in the ATC hierarchy

Level	Code	Title
`1`	J	Antiinfectives for systemic use
`2`	J04	Antimycobacterials
`3`	J04A	Drugs for treatment of tuberculosis
`4`	J04AB	Antibiotics
`5`	J04AB02	Rifampicin

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Code	Route	Amount	Notes
ORAL	Oral	0.6 g
PAREN	Parenteral	0.6 g

Active ingredients in J04AB02

Active Ingredient
Rifampicin
Rifampicin is an active bactericidial antituberculosis drug which is particularly active against the rapidly growing extracellular organisms and also has bactericidial activity intracellularly. Rifampicin inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.

Related product monographs

Document	Type	Information Source
RIFADIN Capsule	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)
RIFADIN Solvent	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)
RIFAREN Capsule	MPI, EU: SmPC	Υπουργείο Υγείας (CY)
RIFASYNT Hard gelatin capsule	MPI, EU: SmPC	Υπουργείο Υγείας (CY)
RIMACTANE Capsule	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)